NCT00350207已完成2 期
A 16-week Randomised, Placebo-controlled, Double-blind, Double-dummy, Parallel-group Study Comparing the Efficacy and Safety of Tiotropium Inhalation Solution Delivered by the Respimat Inhaler (2 Actuations of 2.5 Mcg Once Daily) With That of Salmeterol From the Hydrofluoroalkane Metered Dose Inhaler (2 Actuations of 25 Mcg Twice Daily) in Moderate Persistent Asthma Patients With the B16-Arg/Arg Genotype
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 388
- 试验地点
- 109
- 主要终点
- Change in Mean Weekly Morning Peak Expiratory Flow From Baseline to the End of the Trial
研究概览
简要总结
This is a 16 week multicentre, multinational, randomised, double-blind, double-dummy, placebo-controlled, parallel group study to evaluate the long-term efficacy and safety of tiotropium compared to salmeterol in moderate persistent asthmatic (GINA step 3) patients homozygous for arginine at the 16th amino acid position of the beta-adrenergic receptor (ADRB2). Following an initial 4-week run-in period on salmeterol MDI patients will be randomised into the 16 week double-blind treatment period in which they receive either tiotropium once daily administered from the Respimat inhaler or salmeterol twice daily administered from the hydrofluoro-alkane Metered Dose Inhaler (MDI), or placebo twice daily. After the 16 week treatment period all patients will receive salmeterol MDI twice daily for four weeks.
The patients perform daily morning and evening peak flow (PEF) and Forced Expiratory Volume in the First Second (FEV1) measurements with an electronic peak flow meter throughout the study. Daily data on asthma control and use of rescue medication are recorded using an electronic diary included in the electronic peak flow meter. On study visits the Mini-Asthma Quality of Life Questionnaire (Elizabeth Juniper) is administered, pulse and blood pressure and pre-dose pulmonary function testing (FEV1 and Forced Vital Capacity) are performed.
研究设计
- 研究类型
- Interventional
- 干预模型
- Parallel
- 主要目的
- Treatment
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Inclusion_Criteria:
- •Patients homozygous for arginine at the 16th amino acid position of the beta2 adrenergic receptor (B16 Arg/Arg)
- •All patients must sign and date an Informed Consent Form for the study prior to participation in the trial
- •Male or female outpatients with at least 18 years of age, but not older than 65 years
- •Patients must have a documented history of asthma
- •Patients must be current non-smokers or ex-smokers with a cigarette smoking history of <10 pack-years
- •Patients must be on a maintenance treatment with inhaled corticosteroids with a total daily dose of 400 - 1000 mcg budesonide or equivalent
- •Exclusion_Criteria:
- •Patients with a significant disease other than asthma
- •Patients with a recent history (i.e., six months or less) of myocardial infarction
- •Patients who have been hospitalized for heart failure (New York Heart Association class III or IV) within the past year
- •Patients with any unstable or life threatening cardiac arrhythmia or cardiac arrhythmia requiring intervention or a change in drug therapy within the past year
- •Patients with malignancy for which the patient has undergone resection, radiation therapy or chemotherapy within the last five years. Patients with treated basal cell carcinoma are allowed.
- •Patients with a diagnosis of chronic obstructive pulmonary disease (COPD)
- •Patients with a history of life threatening pulmonary obstruction, or a history of cystic fibrosis or clinically evident bronchiectasis
- •Patients with known active tuberculosis
- •Patients who have undergone thoracotomy with pulmonary resection.
- •Patients who have completed a pulmonary rehabilitation program in the six weeks prior to visit 1 or patients who are currently in a pulmonary rehabilitation program that will not be maintained throughout the duration of the study.
排除标准
- 未提供
结局指标
主要结局
Change in Mean Weekly Morning Peak Expiratory Flow From Baseline to the End of the Trial
时间窗: baseline and after 16 weeks of treatment
Change from baseline in mean weekly morning peak expiratory flow at 16 weeks. Baseline is defined as the last week prior to the randomisation visit
次要结局
- Mean Weekly Morning Peak Expiratory Flow at Week 4(After 4 weeks of treatment)
- Mean Weekly Evening Peak Expiratory Flow at Week 4(After 4 weeks of treatment)
- Mean Weekly Evening Peak Expiratory Flow at Week 8(After 8 weeks of treatment)
- Mean Weekly Morning Peak Expiratory Flow at Week 8(After 8 weeks of treatment)
- Mean Weekly Morning Peak Expiratory Flow at Week 12(After 12 weeks of treatment)
- Mean Weekly Morning Peak Expiratory Flow at Week 16(After 16 weeks of treatment)
- Mean Weekly Evening Peak Expiratory Flow at Week 12(After 12 weeks of treatment)
- Mean Weekly Evening Peak Expiratory Flow at Week 16(After 16 weeks of treatment)
- Mean Weekly Morning Forced Expiratory Volume in 1 Second at Week 4(After 4 weeks of treatment)
- Mean Weekly Morning Forced Expiratory Volume in 1 Second at Week 8(After 8 weeks of treatment)
- Mean Weekly Morning Forced Expiratory Volume in 1 Second at Week 12(After 12 weeks of treatment)
- Mean Weekly Morning Forced Expiratory Volume in 1 Second at Week 16(After 16 weeks of treatment)
- Mean Weekly Evening Forced Expiratory Volume in 1 Second at Week 4(After 4 weeks of treatment)
- Mean Weekly Evening Forced Expiratory Volume in 1 Second at Week 8(After 8 weeks of treatment)
- Mean Weekly Evening Forced Expiratory Volume in 1 Second at Week 12(After 12 weeks of treatment)
- Mean Weekly Evening Forced Expiratory Volume in 1 Second at Week 16(After 16 weeks of treatment)
- Mean Weekly Score for Asthma Control Diary Question "Did You Wake up During the Night Due to Asthma" at Week 4(After 4 weeks of treatment)
- Mean Weekly Score for Asthma Control Diary Question "Did You Wake up During the Night Due to Asthma" at Week 8(After 8 weeks of treatment)
- Mean Weekly Score for Asthma Control Diary Question "Did You Wake up During the Night Due to Asthma" at Week 12(After 12 weeks of treatment)
- Mean Weekly Score for Asthma Control Diary Question "Did You Wake up During the Night Due to Asthma" at Week 16(After 16 weeks of treatment)
- Mean Weekly Score for Asthma Control Diary Question "How Were Your Asthma Symptoms in the Morning" at Week 4(After 4 weeks of treatment)
- Mean Weekly Score for Asthma Control Diary Question "How Were Your Asthma Symptoms This Morning" at Week 8(After 8 weeks of treatment)
- Mean Weekly Score for Asthma Control Diary Question "How Were Your Asthma Symptoms This Morning" at Week 12(After 12 weeks of treatment)
- Mean Weekly Score for Asthma Control Diary Question "How Were Your Asthma Symptoms This Morning" at Week 16(After 16 weeks of treatment)
- Mean Weekly Score for Asthma Control Diary Question "How Were Your Asthma Symptoms During the Day" at Week 4(After 4 weeks of treatment)
- Mean Weekly Score for Asthma Control Diary Question "How Were Your Asthma Symptoms During the Day" at Week 8(After 8 weeks of treatment)
- Mean Weekly Score for Asthma Control Diary Question "How Were Your Asthma Symptoms During the Day" at Week 12(After 12 weeks of treatment)
- Mean Weekly Score for Asthma Control Diary Question "How Were Your Asthma Symptoms During the Day" at Week 16(After 16 weeks of treatment)
- Mean Weekly Score for Asthma Control Diary Question "How Limited Were You in Your Activities Today Because of Your Asthma" at Week 4(After 4 weeks of treatment)
- Mean Weekly Score for Asthma Control Diary Question "How Limited Were You in Your Activities Today Because of Your Asthma" at Week 8(After 8 weeks of treatment)
- Mean Weekly Score for Asthma Control Diary Question "How Limited Were You in Your Activities Today Because of Your Asthma" at Week 12(After 12 weeks of treatment)
- Mean Weekly Score for Asthma Control Diary Question "How Limited Were You in Your Activities Today Because of Your Asthma" at Week 16(After 16 weeks of treatment)
- Mean Weekly Score for Asthma Control Diary Question "How Much Shortness of Breath Did You Experience During the Day" at Week 4(After 4 weeks of treatment)
- Mean Weekly Score for Asthma Control Diary Question "How Much Shortness of Breath Did You Experience During the Day" at Week 8(After 8 weeks of treatment)
- Mean Weekly Score for Asthma Control Diary Question "How Much Shortness of Breath Did You Experience During the Day" at Week 12(After 12 weeks of treatment)
- Mean Weekly Score for Asthma Control Diary Question "How Much Shortness of Breath Did You Experience During the Day" at Week 16(After 16 weeks of treatment)
- Mean Weekly Score for Asthma Control Diary Question "Did You Experience Wheeze or Cough During the Day" at Week 4(After 4 weeks of treatment)
- Mean Weekly Score for Asthma Control Diary Question "Did You Experience Wheeze or Cough During the Day" at Week 8(After 8 weeks of treatment)
- Mean Weekly Score for Asthma Control Diary Question "Did You Experience Wheeze or Cough During the Day" at Week 12(After 12 weeks of treatment)
- Mean Weekly Score for Asthma Control Diary Question "Did You Experience Wheeze or Cough During the Day" at Week 16(After 16 weeks of treatment)
- Morning Pre-dose Forced Expiratory Volume in 1 Second as Measured by Spirometry at Visit 3(After 6 weeks of treatment)
- Morning Pre-dose Forced Expiratory Volume in 1 Second as Measured by Spirometry at Visit 4(After 12 weeks of treatment)
- Morning Pre-dose Forced Expiratory Volume in 1 Second as Measured by Spirometry at Visit 5(After 16 weeks of treatment)
- Morning Pre-dose Forced Vital Capacity as Measured by Spirometry at Visit 5(After 16 weeks of treatment)
- Morning Pre-dose Forced Vital Capacity as Measured by Spirometry at Visit 3(After 6 weeks of treatment)
- Morning Pre-dose Forced Vital Capacity as Measured by Spirometry at Visit 4(After 12 weeks of treatment)
- Systolic Blood Pressure in Conjunction With Spirometry at Visit 5(After 16 weeks of treatment)
- Mini-Asthma Quality of Life Questionnaire (Mini-AQLQ) Overall Score at Visit 3(After 6 weeks of treatment)
- Mini-AQLQ Overall Score at Visit 4(After 12 weeks of treatment)
- Systolic Blood Pressure in Conjunction With Spirometry at Visit 3(After 6 weeks of treatment)
- Systolic Blood Pressure in Conjunction With Spirometry at Visit 4(After 12 weeks of treatment)
- Pulse Rate in Conjunction With Spirometry at Visit 3(After 6 weeks of treatment)
- Mean PEF Variability at Week 8(After 8 weeks of treatment)
- Mean PEF Variability at Week 12(After 12 weeks of treatment)
- Mini-AQLQ Overall Score at Visit 5(After 16 weeks of treatment)
- Diastolic Blood Pressure in Conjunction With Spirometry at Visit 5(After 16 weeks of treatment)
- Pulse Rate in Conjunction With Spirometry at Visit 4(After 12 weeks of treatment)
- Pulse Rate in Conjunction With Spirometry at Visit 5(After 16 weeks of treatment)
- Mean PEF Variability at Week 4(After 4 weeks of treatment)
- Mean PEF Variability at Week 16(After 16 weeks of treatment)
- Diastolic Blood Pressure in Conjunction With Spirometry at Visit 3(After 6 weeks of treatment)
- Diastolic Blood Pressure in Conjunction With Spirometry at Visit 4(After 12 weeks of treatment)
研究者
研究点 (109)
Loading locations...
相似试验
已完成
3 期
Efficacy and Safety of Oral UT-15C Tablets to Treat Pulmonary Arterial HypertensionPulmonary HypertensionNCT00887978United Therapeutics310
已完成
3 期
FREEDOM-C: Oral Treprostinil in Combination With an Endothelin Receptor Antagonist (ERA) and/or a Phosphodiesterase-5 (PDE-5) Inhibitor for the Treatment of Pulmonary Arterial Hypertension (PAH)Pulmonary HypertensionNCT00325442United Therapeutics354
已完成
2 期
Efficacy and Safety of HRS-7535 Tablets in Adults With Diabetic Kidney Disease in Type 2 DiabetesDiabetic Kidney Disease, Type 2 DiabetesNCT06415214Shandong Suncadia Medicine Co., Ltd.281
已完成
3 期
OPN-375 Efficacy and Safety in Adolescents With Bilateral Nasal PolypsBilateral Nasal PolyposisNCT03747458Optinose US Inc.40
终止
2 期
ARAMIS: Actions of tesaglitazaR on fAt Metabolism and Insulin SensitivityType 2 DiabetesNCT00263965AstraZeneca105